Key Drivers
- Strong Liquidity
- Persistent Losses
- High Cash Burn
AIAI Summary
IMNM is a catalyst-driven biotech whose near-term investment case hinges on FDA approval and successful launch of varegacestat, while IM-3050 remains longer-dated, unproven upside; investors should weigh the substantial liquidity runway against rapid cash burn, dilution risk, and a nearly $3 billion valuation that leaves little room for regulatory or execution setbacks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •High Cash Burn
IMNM has strong liquidity and minimal debt, but sustained losses, heavy R&D burn, negative cash flow, and a high book-value multiple make it a high-risk, execution-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Clear downtrend
- •Oversold momentum
- •Critical support
IMNM is in a clear last-month downtrend, but oversold momentum and support near $23.45–$23.50 suggest a possible bounce if it reclaims $24.55–$24.95; a break below support would signal further downside.
Small rebound after reaching deeply oversold conditions near support
Sentiment & News
Key News Insights:
- •New Employee Grants
- •Investor Conference
- •No Data Updates
Immunome expanded its workforce with inducement grants and will engage investors at an upcoming conference, with no new clinical or financial updates disclosed.
The announcements are modestly supportive of operational momentum but offer no immediate fundamental catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings